Glucose Viaflo Baxter (Glucose Monohydrate)

Glucose Viaflo Baxter is indicated for several clinical situations where rapid glucose delivery and fluid replacement are required.

• Treatment of hypoglycemia when oral intake is not feasible.
• Component of parenteral nutrition regimens to supply carbohydrate calories.
• Fluid and electrolyte replacement in patients unable to tolerate oral fluids.
• Support of plasma osmolarity during intravenous therapy.
• Adjunct in perioperative care to maintain blood glucose levels.

Intravenous glucose monohydrate can elicit a spectrum of effects that reflect its role as a rapid energy source and its influence on plasma osmolarity. Most reactions are mild and reversible, while rare events may require medical attention.

Common

• A temporary increase in blood glucose concentration that usually normalizes without intervention.
• Mild gastrointestinal discomfort such as nausea or occasional vomiting shortly after infusion.
• Localized irritation or erythema at the catheter insertion site.

Serious

• Marked hyperglycemia that can progress to osmotic diuresis and dehydration.
• Fluid overload manifesting as pulmonary edema, especially in patients with compromised cardiac function.
• Immediate hypersensitivity reactions, including rash, bronchospasm, or anaphylactic shock.

When using Glucose Viaflo Baxter, clinicians should observe several precautionary measures to minimize risks and ensure appropriate patient monitoring.

• Verify blood glucose level before administration to avoid excessive hyperglycemia.
• Adjust infusion rate in patients with renal or cardiac insufficiency to prevent fluid overload.
• Monitor electrolytes, particularly potassium and sodium, during and after infusion.
• Use aseptic technique to reduce risk of catheter‑related infection.
• Assess for signs of allergic reaction during the first minutes of infusion.
• Consider alternative carbohydrate sources in patients with known glucose intolerance.

Glucose Viaflo Baxter may interact with other medications or clinical conditions, influencing its safety and efficacy.

Avoid

• Co‑administration with high‑dose insulin without glucose monitoring, which can precipitate severe hypoglycemia.
• Simultaneous infusion of hypertonic dextrose solutions, increasing risk of hyperosmolar complications.
• Use in patients with uncontrolled diabetes mellitus when glucose levels are already elevated.

Use with caution

• Concurrent diuretics or potassium‑sparing agents that affect electrolyte balance.
• Medications that prolong QT interval, as rapid glucose shifts may influence cardiac electrophysiology.
• Renal replacement therapy, requiring adjustment of glucose infusion rates.